The FDA issued an untitled letter upbraiding Lilly for Cymbalta consumer and professional ads. A consumer print ad for the brand’s fibromyalgia indication fails to adequately communicate risks of use, ...

Lilly said its “Depression Hurts” ad campaign for Cymbalta is working, helping drive the drug’s gains in share of the crowded market. “Patients have told us, ‘finally, someone understands what I’m ...

US drugmaker Eli Lilly has received a dressing down from the US Food and Drug Administration (FDA) for failing to make the risks of its Cymbalta (duloxetine) clear enough in medical journal ...

INDIANAPOLIS, Indiana — The U.S. Food and Drug Administration has slapped drugmaker Eli Lilly & Co. on the wrist for making “false or misleading claims” in advertisements for Cymbalta, a drug for pain ...

While Eli Lilly's CEO was out lobbying for drug safety, the FDA was posting a letter on its website warning the drug maker to stop making "false and misleading" claims about its antidepressant ...

The FDA has issued another wave of letters demanding changes in drug promotions. Warning letters went out to Bayer, Amylin Pharmaceuticals, Eli Lilly and Cephalon, ordering the companies to stop using ...